Meropenem

Introduction Overview

Generic Name

meropenem

Brand Name

Merrem, Merrem Novaplus

Dosage Form

intravenous powder for injection (500 mg; 1000 mg; 2 g)

Drug Class

Carbapenems

Pharmacokinetics

Absorption:
Meropenem is not administered orally and thus has no gastrointestinal absorption profile; it is given exclusively via intravenous infusion to ensure 100% bioavailability. This parenteral administration bypasses the gastrointestinal tract, delivering the active drug directly into systemic circulation, enabling rapid attainment of therapeutic plasma levels. Pharmacodynamic response is influenced by infusion duration, and dosing regimens are customized to maintain adequate plasma concentrations above the minimum inhibitory concentration (MIC) for target pathogens.

Distribution:
Following intravenous administration, meropenem demonstrates extensive tissue distribution, characterized by a volume of distribution (Vd) approximating total body water (~0.25 L/kg). It crosses multiple biological barriers, achieving therapeutic concentrations in diverse tissues and fluids including cerebrospinal fluid (especially when the meninges are inflamed), lung, muscle, and intra-abdominal compartments. Approximately 2% of meropenem is bound to plasma proteins, which is low, facilitating free drug availability for antimicrobial activity. Its penetration into the central nervous system is particularly notable in bacterial meningitis, allowing effective treatment of central infections.

Metabolism:
Meropenem undergoes minimal metabolic transformation. The principal metabolic event involves hydrolysis of the β-lactam ring by renal dehydropeptidase-1 (to a limited extent), but unlike imipenem, meropenem is stable against dehydropeptidase-I and does not require concomitant administration of a dehydropeptidase inhibitor such as cilastatin. This stability reduces the formation of inactive or nephrotoxic metabolites. The limited metabolism results in a majority of the administered dose being excreted unchanged.

Elimination:
Meropenem is primarily eliminated by the kidneys through active tubular secretion and glomerular filtration. Approximately 70% of the administered dose is recovered unchanged in urine within 12 hours post-dose. The elimination half-life in healthy adults is approximately 1 hour but may be prolonged in patients with impaired renal function. Dosage adjustments are recommended in patients with renal insufficiency to avoid drug accumulation and toxicity. The drug is not significantly cleared by hemodialysis or peritoneal dialysis, necessitating additional dosing considerations during these procedures.

Dosage Forms

Available Dosage Forms:
Meropenem is available solely as a sterile intravenous powder for injection to be reconstituted prior to infusion. The powder form is provided in multiple vial strengths: 500 mg, 1000 mg (1 g), and 2 g for flexible dosing tailored to infection severity and patient characteristics.

Dosages for Adults and Adolescents:
The recommended dosage depends on the type and severity of the infection. For adults and children aged 3 months and older, typical regimens include 500 mg to 2 g intravenous infusions administered every 8 hours as a 15 to 30-minute infusion. For instance, complicated intra-abdominal infections and meningitis may require higher dosage regimens (e.g., 2 g every 8 hours), whereas skin and soft tissue infections may be managed with lower doses (e.g., 500 mg every 8 hours). Treatment duration varies based on clinical response but frequently extends from 7 to 14 days.

Specific Patient Populations:
In pediatric patients aged 3 months and older, dosing is weight-based, commonly 10 to 40 mg/kg every 8 hours depending on infection severity and site, with maximum adult dose limits applied. Patients with renal impairment require dosage adjustments based on creatinine clearance to prevent accumulation and toxicity; dose frequency or amount is reduced accordingly. Meropenem is not recommended for use in neonates younger than 3 months due to limited safety data. No dosage modification is generally required for hepatic impairment.

Clinical Guidelines:
Administration must be intravenous only; the powder should be reconstituted and diluted according to manufacturer instructions immediately before use to ensure drug stability and efficacy. Infusion duration typically spans 15 to 30 minutes, with extended infusions employed in certain resistant infections to optimize pharmacodynamics.

Mechanism Of Action

Meropenem is a broad-spectrum carbapenem antibiotic belonging to the β-lactam class that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It achieves this by binding with high affinity to penicillin-binding proteins (PBPs), essential enzymes located inside the bacterial cell wall responsible for cross-linking peptidoglycan strands. By acylating these PBPs, meropenem effectively inhibits the transpeptidation step of peptidoglycan synthesis, leading to defective cell walls and ultimately bacterial lysis.

At the molecular level, meropenem’s β-lactam ring structure mimics the D-Ala-D-Ala terminus of peptidoglycan precursors, competitively binding to PBP catalytic sites. This binding is highly stable and less susceptible to cleavage by many β-lactamases, including extended-spectrum β-lactamases (ESBLs) and AmpC enzymes, conferring resistance to enzymatic degradation. Its carbapenem nucleus provides enhanced stability compared to other β-lactams, and it is structurally resilient against renal dehydropeptidase-1, negating the need for coadministration of inhibitors.

The antibiotic is effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria due to its strong affinity for a variety of PBPs across different species. It inhibits bacterial growth by disrupting cell wall integrity, a vital process for bacterial survival. This results in rapid bactericidal action. Additionally, meropenem penetrates well into cerebrospinal fluid, making it effective for treating central nervous system infections such as bacterial meningitis.

Comparatively, meropenem has a broader spectrum and better stability against β-lactamases than many cephalosporins and penicillins, enhancing its clinical utility against multidrug-resistant organisms. Clinical studies have demonstrated its efficacy against complicated intra-abdominal infections, nosocomial pneumonia, and bacterial meningitis, affirming its role as a critical agent in the carbapenem class for severe, resistant infections.

Pharmacological Actions

Bactericidal activity through inhibition of bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs).
Broad-spectrum antibacterial activity, effective against Gram-positive, Gram-negative, and anaerobic bacteria.
Stable to many β-lactamases, including extended-spectrum β-lactamases (ESBLs) and AmpC enzymes.
Rapid bactericidal effect with time-dependent killing dynamics.
Penetrates into cerebrospinal fluid effectively, enabling treatment of bacterial meningitis.
Minimal protein binding (~2%), allowing high free drug concentrations.
Not metabolized extensively; primarily excreted unchanged by renal elimination.
Does not require coadministration of dehydropeptidase inhibitor due to stability against renal enzymes.
Useful for treatment of severe systemic and localized bacterial infections.
Reduces bacterial resistance risks when dosed appropriately with proper clinical stewardship.
Clinical efficacy demonstrated in complicated intra-abdominal infections and skin/soft tissue infections.
Compatible with intravenous administration with flexible dosing intervals.
Exhibits time-dependent pharmacodynamics with efficacy linked to duration plasma concentrations exceed MIC.

Therapeutic Or Clinical Uses

Treatment of complicated intra-abdominal infections caused by susceptible bacteria.
Management of bacterial meningitis with or without bacteremia in adults and children 3 months and older.
Therapy for complicated skin and soft tissue infections.
Treatment of nosocomial pneumonia and ventilator-associated pneumonia.
Empiric therapy for febrile neutropenia in immunocompromised patients.
Used to treat severe infections caused by multidrug-resistant Gram-negative organisms.
Management of bacterial infections where other antibiotics are ineffective or contraindicated.
Treatment of urinary tract infections caused by susceptible pathogens.
Used in sepsis or bacteremia due to susceptible bacterial pathogens.
Therapy for infections involving the central nervous system given good CNS penetration.
Alternative treatment option for patients intolerant to penicillins or cephalosporins considering cross-reactivity.
Treatment for patients with mixed aerobic and anaerobic infections due to broad spectrum activity.
Effective in hospital-acquired infections requiring intravenous antimicrobial therapy.
Utilized in infections requiring bactericidal antibiotics for rapid bacterial clearance.

Side Or Adverse Effects

Headache and dizziness occurring during or after intravenous infusion.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and constipation.
Hypersensitivity reactions ranging from mild rash to severe anaphylaxis and skin reactions.
Development of Clostridioides difficile-associated diarrhea with prolonged use.
Injection site reactions including pain, swelling, burning, or irritation.
Seizures, particularly in patients with pre-existing central nervous system disorders or renal impairment.
Fungal infections such as oral thrush due to disruption of normal microbial flora.
Anemia or other hematologic abnormalities like leukopenia or thrombocytopenia.
Elevations in liver enzymes and rare instances of hepatic dysfunction.
Confusion, weakness, numbness, or paresthesia as signs of neurotoxicity in vulnerable patients.
Potential Stevens-Johnson syndrome or other severe skin disorders (rare).
Allergic responses including hives, swelling of face, lips, tongue, or throat.
Possible renal function impairment necessitating monitoring during therapy.
Unusual bruising or bleeding may indicate hematologic or coagulation abnormalities.
Fever and swollen lymph nodes as signs of systemic drug hypersensitivity reactions.

Precautions

Assess for previous allergic reactions to carbapenems, penicillins, or cephalosporins before administration.
Use with caution in patients with a history of seizures, epilepsy, or CNS disorders.
Adjust dosage in patients with impaired renal function to avoid toxicity.
Monitor renal function periodically during treatment, especially in elderly or renal-compromised patients.
Evaluate patients regularly for the development of Clostridioides difficile-associated diarrhea.
Avoid abrupt discontinuation despite symptom improvement to prevent resistance development.
Inform patients about potential side effects and advise to report severe or persistent symptoms.
Cautiously use in patients on a sodium-restricted diet due to sodium content in some formulations.
Ensure proper reconstitution and infusion techniques to prevent local reactions or reduced efficacy.
Monitor hematologic parameters during prolonged therapy due to risk of anemia or other blood disorders.
Consider risks versus benefits in pregnant or breastfeeding women, consulting current clinical guidelines.
Avoid concomitant use with valproic acid or divalproex sodium without close monitoring due to interaction.
Be vigilant for signs of superinfections caused by non-susceptible organisms.
Use cautiously in patients with congestive heart failure due to fluid volume from intravenous dosing.
Inform patients about potential dizziness or confusion that could impair activities requiring alertness.

Warnings

Do not use meropenem if allergic to meropenem or other carbapenems, or have a history of life-threatening reactions to β-lactam antibiotics.
Risk of serious hypersensitivity reactions including anaphylaxis; emergency treatment should be accessible.
Potential for Clostridioides difficile-associated diarrhea, which can occur during or after treatment.
Seizures may occur, especially in patients with CNS disorders or renal impairment; monitor closely.
Use only as directed; misuse can lead to antimicrobial resistance and treatment failure.
Not effective against viral infections including influenza or common cold; inappropriate use should be avoided.
Avoid use of certain meropenem brands in patients on low-sodium or sodium-free diets due to formulation content.
Monitor for severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Concurrent use with valproic acid can reduce valproic acid serum concentrations, risking seizures.
Avoid abrupt cessation; incomplete therapy may promote resistant bacterial strains and relapse.
Use caution in patients with renal impairment; dose adjustment required to prevent toxicity.
Do not use in neonates younger than 3 months due to insufficient safety and efficacy data.
Meropenem may cause dizziness, confusion, or weakness; avoid hazardous activities until effects are known.
Administer under supervision by healthcare professionals to monitor for adverse reactions.
Discontinue immediately if severe allergic or hypersensitivity reactions develop.

Contraindication

Hypersensitivity to meropenem, other carbapenems, or any component of the formulation.
History of life-threatening allergic reactions (anaphylaxis) to β-lactam antibiotics including penicillins and cephalosporins.
Known allergy to imipenem, cilastatin, or drugs structurally related to meropenem.
Certain meropenem brands contraindicated in patients requiring low-sodium or sodium-free diets.
Use contraindicated in neonates under 3 months of age due to lack of established safety.
Patients with previous severe dermatologic reactions to β-lactams should avoid meropenem.
Patients with history of seizures without appropriate concomitant treatment should avoid use.
Contraindicated if there is previous history of severe drug-induced hypersensitivity to meropenem.
Avoid concomitant use with valproic acid in patients at high risk of seizures without monitoring.
Known hypersensitivity to any stabilizers or excipients used in meropenem powder formulation.

Drug Interactions

Valproic acid and divalproex sodium: meropenem decreases serum concentrations, reducing seizure control efficacy.
Probenecid may decrease renal clearance of meropenem, increasing plasma concentrations and risk of toxicity.
Other nephrotoxic agents: concomitant use may enhance renal toxicity; monitor renal function.
Anticoagulants (e.g., warfarin) may have altered effects when used with meropenem; monitor coagulation parameters.
Live bacterial vaccines may have reduced efficacy or increased risk of infection when used concurrently.
Potential additive CNS toxicity with other neurotoxic drugs (e.g., cyclosporine, amphotericin B).
Concomitant use with diuretics may potentiate risk of electrolyte disturbances.
Use with caution with other antibiotics that have synergistic or antagonistic effects.
No significant pharmacokinetic interactions with common analgesics or antipyretics.
May interfere with certain laboratory tests, especially those measuring creatinine or hepatic enzymes.
Altered metabolism of oral contraceptives is unlikely but patient counseling recommended.
Herbal supplements with potential CNS depressant effects should be used cautiously.
Interactions with immunosuppressants may require close monitoring for infection control.
Adjust dosage and monitor patients receiving concomitant medications cleared renally.
Consult comprehensive drug interaction resources prior to initiating meropenem with polypharmacy.

Preparations Of The Drug

Meropenem is manufactured as a sterile, lyophilized powder for intravenous infusion.
Available vial strengths include 500 mg, 1000 mg (1 g), and 2 g for dose flexibility.
Powder formulations require reconstitution with sterile water or appropriate diluents before administration.
The reconstituted solution is further diluted typically with normal saline or dextrose solutions for infusion.
Preparations are designed for intravenous administration only – no oral or intramuscular formulations.
Stability of the reconstituted solution is limited; usually must be used within a specified timeframe (e.g., 12 hours refrigerated).
Commercial formulations for use in hospital settings and outpatient intravenous therapy.
No preservative-containing formulations; thus, strict aseptic technique is required during preparation.
Packaging may include single-dose vials to minimize contamination risk.
Some formulations are packaged with dosing instructions for weight-based pediatric dosing.
Manufacturers provide data on compatibility with intravenous fluids and other drugs for co-infusion considerations.
Instructions specify storage conditions for powder and reconstituted forms to preserve potency.
Available under brand names Merrem and Merrem Novaplus with regulatory approvals worldwide.
The sodium content per vial varies; care advised in patients on sodium-restricted diets.
Preparations are intended for healthcare provider administration or trained caregiver use at home.